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Evidence is presented that the topoisomerase inhibitors novobiocin and coumermycin inhibit the 
production of double-strand breaks in mouse mastocytoma cell nuclear DNA by the anticancer drug 
4 ’ [(9-acridinyl)amino]-methanesulphon-m-anisidide (mAMSA). Novobiocin did not inhibit resealing of 
DNA breaks induced by mAMSA. It is suggested that mAMSA intercalation into DNA induces the action 
of a type II topoisomerase. mAMSA and oAMSA were equally effective in breaking the DNA in isolated 
nuclei. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
The anticancer drug 4’ [(9-acridinyl)amino]- 
methanesulphon-m-anisidide (mAMSA) induces 
breaks in the nuclear DNA of cells or isolated 
nuclei, probably after intercalation of the drug in- 
to DNA [l]. In either case the broken DNA 
becomes linked to protein [2,3]. Because the 
protein-DNA cross-links produced in isolated 
nuclei by mAMSA are rapidly resealed upon dilu- 
tion of the drug it has been suggested that they are 
intermediates in the response to mAMSA that are 
exposed when DNA is prepared from the cells 
[2,3]. These and other observations [l] have led to 
the suggestion that a topoisomerase breaks, and 
becomes linked to, DNA in mAMSA-treated cells 
or nuclei in response to the altered DNA structure 
caused by drug intercalation [2,3]. In support of 
this possibility we present evidence that mAMSA 
induces double-strand breaks in the DNA of 
isolated PY8 15 mouse mastocytoma cell nuclei and 
that known topoisomerase inhibitors negate the ac- 
tion of mAMSA. These observations suggest hat 
mAMSA induces the action of a type II 
topoisomerase. 
* To whom correspondence should be addressed 
Novobiocin and coumermycin were products of 
Sigma. mAMSA and oAMSA were kind gifts from 
Dr B.C. Baguley. Log-phase PY815 mouse 
mastocytoma cells were grown as in [4]. Nuclei 
were prepared from the cells as in [3] but with 
5 mM EGTA and resuspended in their nuclei buf- 
fer with 5 mM EGTA prior to drug treatment or 
lysis. To measure the effects of drugs on DNA, 
nuclei from l-3 x lo6 cells in 0.1-0.2 ml buffer 
were treated with drugs for 10 min as described in 
the text then diluted to 3 ml with nuclei buffer, lys- 
ed by adding 2 ml of neutral lysis buffer (Li 
dodecylsulphate (2% w/v) 20 mM Tris-HCl buf- 
fer (pH S.O), 20 mM NaCl, 20 mM Na + EDTA) 
and rocked gently for 2 h at 20°C in darkness. 
Lysis in neutral solutions was used to reveal 
double-strand breaks in DNA. DNA breakage was 
measured with a simple viscometer as previously 
described [5]. The validity of measuring viscosity 
to detect DNA breakage has since been confirmed 
VI. 
3. RESULTS 
We previously used an alkaline lysis procedure 
and viscometry to detect single-strand breaks pro- 
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duced in intact cellular DNA by mAMSA treat- 
ment [5]. At that time attempts to use neutral lysis 
to detect he production of double-strand breaks in 
the DNA of mAIMSA-treated cells was thwarted by 
gelatinous lumps that failed to disperse in the 
lysates [5]. A similar problem was encountered 
when isolated nuclei in small volumes (0.1-0.2 ml) 
were treated with mAMSA and subsequently lysed 
in 5 ml neutral lysis solution. However the pro- 
blem was overcome by diluting and dispersing the 
mAMSA-treated or untreated nuclei with 3 ml of 
nuclei buffer immediately prior to addition of the 
neutral lysis mixture, when a uniformly viscous 
neutral nuclei lysate suitable for viscosity measure- 
ment was obtained (see section 2). 
Fig.1 shows that the viscosity of neutral lysates 
of isolated PY8 15 mouse mastocytoma cell nuclei 
increased with increasing concentrations of nuclei. 
Fig.1 also illustrates the effect of pretreating the 
isolated nuclei with mAMSA for 10 min on the 
viscosity of subsequent neutral lysates. It is clear 
that mAMSA treatment caused a substantial 
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Fig.1. Effect of mAMSA on the viscosity of neutral 
nuclei lysates. Nuclei for this experiment were isolated 
with 5 mM ATP. Incubation was at 30°C. (A) Nuclei 
incubated 10 min; (A) nuclei treated with mAMSA for 
10 min; (+) nuclei incubated with pancreatic 
deoxyribonuclease I (30 pg/ml) for 10 min. 
Table 1 
Resealing of mAMSA-induced breaks in the DNA of 
isolated nuclei 
Treatmenta 
Untreated nuclei 
+ 4 PM mAMSA 
+ 4,uM mAMSA, then 
30-fold diluted 
a 3 x lo6 nuclei per assay 
b Mean of 3 measurements 
Flow rate (min)b 
4.42 
2.14 
4.43 
reduction in the viscosity of the nuclei lysates con- 
sistent with the introduction of double-strand 
breaks in the nuclear DNA, a result that paralleled 
earlier demonstrations that mAMSA produces 
double-strand breaks in the DNA of intact cells 
[2,4,5]. Preincubating the nuclei for 10 min with 
30 fig/ml pancreatic deoxyribonuclease I (EC 
3.1-3.5) prior to lysis dramatically reduced 
viscosity confirming that it was due to DNA. 
When PY815 cell nuclei pretreated with 4 PM 
mAMSA for 10 min in 0.1 ml buffer were diluted 
to 3 ml, reincubated at 30°C for 5 min, then lysed 
with 2 ml neutral lysis solution, there was a 
recovery in the viscosity of the lysates relative to 
that of mAMSA-treated nuclei indicating the re- 
joining of breaks in the nuclear DNA (table 1). A 
similar observation was made with L1210 cell 
nuclei in [5]. 
Because the production of rejoinable double- 
strand breaks in nuclear DNA could be explained 
by the action of a topoisomerase [7], the ability of 
the topoisomerase inhibitors novobiocin and 
coumermycin to negate the effects of mAMSA on 
nuclear DNA was examined. Preincubation of 
isolated nuclei for 1 min with lOO,~g/ml of either 
novobiocin or coumermycin prior to the addition 
of 4pM mAMSA substantially prevented the 
reduction in viscosity normally seen when nuclei 
treated with mAMSA alone for 10 min were lysed 
in neutral solution (table 2A,B). Concentrations of 
the inhibitors below 20,~g/ml were ineffective. 
Novobiocin or coumermycin (100 pg/ml) did not 
prevent the rejoining of DNA when the drugs were 
added to mAMSA-treated nuclei just prior to dilu- 
tion and reincubation to allow DNA rejoining 
(table 2C). 
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Table 2 
Inhibition of nuclear DNA breakage by novobiocin or 
coumermycin 
Treatmenta Flow rate 
(min)’ 
(A) Control (no drugs) 5.55 
+ Coumermycin (100 fig/ml) 6.18 
+ mAMSA (4 PM) 2.02 
+ Coumermycin + mAMSA 4.72 
(B) Control (no drugs) 5.16 
+ Novobiocin (100 &ml) 5.41 
+ mAMSA (4 PM) 2.51 
+ Novobiocin + mAMSA 4.23 
(C) Control (no drugs) 
+ mAMSA (4 FM) 
+ Novobiocin (100 pug/ml) 
+ mAMSA then novobiocin 
4.05 
2.44 
4.12 
(100 pg/ml) during rejoining 4.08 
a A and B = 3 x lo6 nuclei per assay. Incubation with 
drugs for 10 min at 30°C. C = 2.5 x lo6 nuclei per 
assay 
b Mean of 3 measurements 
The effect of oAMSA on DNA breakage in 
isolated nuclei was also measured. This andlogue 
of xnAMSA is dramatically less cytotoxic than 
mAMSA and it has much less effect on DNA in in- 
tact cells [2,8]. Treatment of isolated PY815 cell 
nuclei with o- or mAMSA was almost equally ef- 
fective in reducing the viscosity of subsequent 
neutral lysates over a range of drug concentrations 
(fig.2). 
4. DISCUSSION 
In an earlier publication we reported unsuc- 
cessful attempts to develop an isolated nuclei 
system sensitive to the drug mAMSA 181. Subse- 
quently, we inadvertently found that mAMSA can 
be demonstrated to break the DNA in isolated 
PY815 mouse mastocytoma cell nuclei if the 
calcium chelating agent EGTA is included in the 
medium used to isolate nuclei. While our research 
was in progress authors in [3] reported that mAM- 
SA breaks the DNA in isolated L1210 cell nuclei 
and these authors also included EGTA in their 
nuclei medium. It appears likely that EGTA is 
essential to inhibit Cecil-de~nd~t DNA en- 
donucleases in nuclei preparations in order to 
detect breakage of DNA induced by mAMSA [9]. 
However, despite the inclusion of EGTA, isolated 
nuclei still appeared to contain some broken DNA 
since the viscosity of neutral PY815 cell nuclei 
lysates was lower than that of an equivalent 
number of whole cells suggesting that some DNA 
breakage occurred during the isolation of nuclei; 
Furthermore, the reduction in viscosity of lysates 
of intact cells after treating cells with mAMSA was 
greater than that obtained when isolated nuclei 
were treated with mAMSA. We believe that these 
effects are probably a consequence of unavoidable 
breaking of some of the .supercoiled loops in 
nuclear DNA during the preparation of nuclei so 
that DNA in the loops is no longer distorted by 
mAMSA intercalation and therefore not attacked 
by topoisomerase. In some experiments, in an at- 
tempt to induce repair of nicks in DNA; 5 mM 
ATP was included in all of the nuclei isolation and 
incubation buffers. This produced nuclei lysates 
with higher viscosities and a greater effect of 
USA-treatment on viscosity was observed. 
However it did not restore the viscosity to that pro- 
duced by an equivalent number of whole cells. 
Both authors in [3] and [lo] were unable to avoid 
some breakage of nuclear DNA during preparation 
of L1210 cell nuclei. 
Our results with novobi~in and coumermycin 
together with earlier demonstrations that mAMSA 
causes double-strand breaks in nuclear DNA [2,4] 
(A IS I 
Fig.2. Comparison of the effects of o- and mAMSA on 
the viscosity of nuclei Iysates: (A) 2.2 x lo6 nuclei per 
assay; (B) 2 x lo6 nuclei per assay; (0) oAMSA-treated 
nuclei; (0) mAMSA-treated nuclei. 
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and that protein is linked to the DNA fragments 
from mAMSA-treated cells or nuclei [2,3] suggest 
that a type II topoisomerase may be responsible 
for breaking the DNA in mAMSA-treated cells or 
nuclei because ukaryotype I topoisomerases cause 
only single-strand iscontinuities in DNA [7]. 
However, whether the cytotoxic action of mAMSA 
actually results from topoisomerase action and 
DNA breakage in intact cells remains to be 
estab~shed. It is also possible that intercalated 
mAMSA prevents the resealing of topoisomerase 
II cross-linked DNA in cells leading to overt 
chromosome damage and rearrangement which is 
ultimately responsible for cell death [I 1,121. The 
greater susceptib~ity of S phase cells to low con- 
centrations of mAMSA [13,14] is consistent with 
the idea that interference with topoisomerase ac- 
tion might explain the action of mAMSA since 
topoisomerases are known to be required during 
DNA synthesis [7] and interference with their func- 
tion at that time would probably have dramatic 
consequences on DNA replication, chromosome 
assembly and cell survival. 
The fact that oAMSA breaks the DNA of 
isolated nuclei as effectively as mAMSA, although 
it is substantially ess cytotoxic to intact cells than 
mAMSA, suggests that the c~oto~city of these 
drugs may not be related to DNA breakage. 
However, oAMSA may penetrate cells poorly, or 
be more rapidly inactivated in the cytoplasm and 
hence fall to enter the nucleus, therefore no 
definitive statement regarding the actual 
m~hanism of c~oto~city of the drugs can yet be 
made. It would be worthwhile to identify the exact 
reason for the different activities of o- and mAM- 
SA since it might also limit the action of mAMSA 
to some extent. 
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